Please login to the form below

Letermovir

This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis ’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate

Latest news

CHMP backs MSD’s CMV infection treatment

Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved
Merck says drug for CMV in transplant patients hits targets

Merck says drug for CMV in transplant patients hits targets. Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked
Merck & Co pays €110m upfront for AiCuris' CMV portfolio

Merck &Co pays 110m upfront for AiCuris' CMV portfolio. Lead candidate is orphan drug letermovir for transplant patients. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Pharma deals during October 2012

Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Client Services Director - Med Comms: Great salary and bebefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Account Manager: £40, 000 - £45, 000 benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Business Unit Head, Medical Communications, London: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Editorial Director – Medical Education (MedComms): Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Subscribe to our email news alerts

PMHub

Add my company

Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....